AC
AKTX

Armistice Capital’s Akari Therapeutics AKTX Stock Holding History

Armistice Capital’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38,922
Closed -$200K – 339
2026
Q1 		$200K Sell
38,922
-29,177
-43% -$273K ﹤0.01% 227
2025
Q4 		$787K Buy
+68,099
New +$1.58M 0.01% 192
2023
Q1 		– Sell
-4,338
Closed -$1.63M – 228
2022
Q4 		$1.63M Sell
4,338
-1,025
-19% -$424K 0.03% 120
2022
Q3 		$2.7M Buy
+5,363
New +$4.42M 0.05% 117

Other funds holding AKTX

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $673M AUM 55.24% 1-Year Est. Return

Armistice Capital's AKTX Position: Q2 2026 in Review

Armistice Capital sold out of Akari Therapeutics (AKTX) in Q2 2026, closing a stake of 38,922 shares — an estimated $200K sold.

Armistice Capital first reported a position in AKTX in Q3 2022 and held it in 4 quarters. The position peaked at $2.7M in Q3 2022. 9 funds tracked by Wall St. Rank hold AKTX as of Q2 2026.

  • Armistice Capital reported no remaining Akari Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Armistice Capital sold 38,922 Akari Therapeutics shares in Q2 2026, an estimated $200K.
  • Armistice Capital first reported a position in Akari Therapeutics in Q3 2022 and held it in 4 quarters.
  • Armistice Capital's Akari Therapeutics position peaked at $2.7M in Q3 2022.
  • 9 funds tracked by Wall St. Rank held Akari Therapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.